Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

NCT00485407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine Hydrochloride

Sponsor

Eli Lilly and Company